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The expression and function of P450 enzymes at the neurovascular unit have a key role in
drug resistance and brain cell viability.
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Over the past decades, the significance of cytochrome P450 (CYP) enzymes
has expanded beyond their role as peripheral drug metabolizers in the liver
and gut. CYP enzymes are also functionally active at the neurovascular
interface. CYP expression is modulated by disease states, impacting
cellular functions, detoxification, and reactivity to toxic stimuli and brain
drug biotransformation. Unveiling the physiological and molecular
complexity of brain P450 enzymes will improve our understanding of the
mechanisms underlying brain drug availability, pharmacological efficacy,
and neurotoxic adverse effects from pharmacotherapy targeting brain
disorders.
Introduction
The blood–brain barrier (BBB) and the blood–cerebrospinal fluid (CSF) barrier regulate the
composition of the brain milieu. Through structural modifications, including the expression
of tight junctions, these central nervous system (CNS) barriers restrict the diffusion of numerous
drugs and xenobiotics into the brain [1]. It is well established that the cells of the BBB and blood–
CSF barriers express ATP-dependent, membrane-bound efflux transporters, which control drug
penetration into the brain. It has been extensively documented that lipophilic compounds aimed
at CNS therapy are substrates for drug efflux transporters that are expressed at the luminal side of
the cerebrovasculature. This is considered one of the mechanisms contributing to pharmacore-
sistance in CNS disorders [2–4]. New evidence has shown that brain P450 enzymes also have a
significant role in pharmacotherapy. CYP enzymes are heme-containing proteins that, alongside
their role of drug metabolism in the liver, are functionally active at the neurovascular unit [5–8],
and are also expressed in other brain cells [9–11]. In contrast to drug transporters, whose
functions impact the pharmacokinetic properties of a drug, CYP enzymes can also have a
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metabolite, which changes the affinity and downstream efficacy
on a specific target [7,8]. Furthermore, the identification of xeno-
biotic-metabolizing enzymes in the human brain raises the ques-
tion of whether these enzymes have a direct impact on disease
physiology or progression [9].
Approximately 15 CYP isotypes, subdivided into three families,
are known to be involved in drug metabolism [12,13]. Intracellular
CYPs were initially described in hepatocytes [14]. CYP localization
at the cellular and subcellular levels was subsequently demonstrat-
ed in the brain [7,8,11,15,16]. In the human liver, CYP2C9,
CYP2C19, CYP2D6, CYP1A2, and CYP3A4 are responsible for
the oxidative metabolism of most xenobiotic substrates. CYP3A4
is one of the most abundant enzymes in the liver and intestine,
and is responsible for the metabolism of not only a large number of
drugs, but also endogenous compounds, such as prostaglandins,
steroid hormones, and fatty acids [12]. Similarly, in the brain, CYPs
are responsible for the oxidative metabolism of exogenous sub-
strates (e.g., xenobiotics, dietary components, and pollutants) and
endogenous substrates (e.g., steroids, cholesterol, and bile acids),
impacting neurological disorders (Fig. 1).
Cytochrome P450 exerts the following activities within a cata-
lytic cycle (Fig. 2) [13]: (i) the first catalytic activity of CYP
enzymes, acting as mono-oxygenases, is to activate molecular
oxygen with electrons from NADPH via NADPH-CYP450 reduc-
tase, and insert one atom of molecular oxygen into the substrate;
(ii) the second catalytic activity, commonly referred to as the
oxidase activity, involves electron transfer from reduced
CYP450 to molecular oxygen with the formation of a superoxide
anion radical and H2O2; and (iii) the third catalytic activity of theNeurologic
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FIGURE 1
Factors regulating cytochrome P450 (CYP450) enzymes in the brain. Brain bioava
response is not only linked to brain P450 enzymes, but also indirectly influenced by
endogenous factors or regulators (e.g., hormones, neurotransmitters, biological cl
constituents, substances of abuse, or pesticides); (iii) demographics (e.g., genetics
epilepsy, psychiatric diseases, neurodegenerative disease, or stroke).
1610 www.drugdiscoverytoday.comP450 system, known as reductase activity, involves direct electron
transfer to reducible substrates, such as quinones, and proceeds
under anaerobic conditions.
Earlier studies were conducted to demonstrate the presence and
metabolic functions of CYP450 and CYP450-dependent monoox-
ygenases in rat olfactory mucosa (OM) compared with the liver
[17]. Interestingly, results showed specific activities toward phen-
acetin, chlorzoxazone, and dextromethorphan to be higher in OM
compared with in the liver. However, lauric acid and testosterone
metabolic activity was similar in both tissues, and tolbutamide was
lower in OM [17]. Considerable differences were observed with
regard to mRNA expression of P450 isoforms, including CYP1A1,
2G1, 2B21, and 4B1; these isoforms were expressed in OM, whereas
CYP2C6, 2C11, 2D2, 3A1, 3A2, and 4A1 mRNA was found only in
the hepatic tissue [17]. Although the hepatic and brain CYP iso-
forms are broadly identical, functional differences can occur [18].
It was suggested that local brain metabolism of drugs at their site of
action influences the therapeutic efficacy independently from
liver metabolism, and that differences in brain CYP enzymes
contribute to variability in brain–drug responses [9,19,20].
Neurovascular expression of CYP450 enzymes
To elucidate the distribution of CYPs at the neurovascular juncture,
initial studies were performed by Ghersi-Egea and colleagues to
explore the fundamental aspects of drug-metabolizing enzymes in
human and rat brain tissue or microvessels [6,21]. Total CYP was
found to be at least nine times higher in the mitochondrial fraction
than in the microsomal subcellular fractions when six regions of the
human brain were analyzed post autopsy [6]. Another report sug-
gested the activities of drug-metabolizing enzymes to be significantal disorders
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ilability of systemically administered drugs may be P450 dependent. Drug
 factors that independently or synergistically affect CYP enzymatic activity: (i)
ock, or cerebral blood flow); (ii) exogenous factors (e.g., xenobiotics, dietary
, age, gender, ethnicity or race); and (iv) disease-specific factors (e.g., cancer,
Drug Discovery Today  Volume 21, Number 10 October 2016 REVIEWS
NADP+ Reduced flavoprotein
CYP450 reductase
Oxidized flavoproteinNADPH
RH
CO
CO CYP450(Fe2+)
CYP450(Fe3+)
CYP450(Fe3+)
CYP450(Fe3+)
CYP450(Fe2+)
RH
ROH
Oxidized
drug
DRUG (R)
RH
O2
H2O
2H+
e–
O2
drug (RH) complex
CYP450
Drug Discovery Today 
FIGURE 2
The cytochrome P450 (CYP450) catalytic cycle. The P450 cytochrome enzymes chemically oxidize or reduce drugs using a reactive heme ring, with an iron atom as
the ultimate electron acceptor or donor and NADPH as a necessary co-factor [13]. These enzymes are also called mixed function oxidases, and are similar to other
enzymes involved in electron transport.
Adapted from [124].
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hypophysis, pineal gland, and median eminence) and in cerebral
microvessels [10]. These findings also supported the hypothesis that
drug-metabolizing enzymes are located at blood–brain interfaces,
where they form an ‘enzymatic and metabolic barrier’ [6,7,10].
In contrast to peripheral organs of metabolic competence, the
brain is not ‘homogeneous’ because each region differs in cellular
composition, cell density, and function. As a result, the expression
of CYP varies (Table 1) [10,11,18]. Dutheil et al. showed selective
P450 expression in neuronal and glial cells in several cerebral
regions [9,22]. The enzymes studied were CYP1B1, CYP2D6,
CYP2E1, CYP2J2, CYP2U1, and CYP46A1, with pronounced het-
erogeneous distributions in different brain areas [9,22]. Expression
of P450s in astrocytes has also been reported [5,6]. The latter is
relevant to the notion of a metabolic barrier, because astrocytic
end-feet envelop the cerebrovasculature. The circumventricular
organs also express CYP1A, CYP1B, and CYP2D [10,16,23,24].
These findings are suggestive of evolved protection against harm-
ful xenobiotics [18].
CYP distribution patterns across various brain regions are docu-
mented in both humans and rodents (Table 1). For example,
evidence exists suggesting that, in rodents, CYP1A1 is mainly
expressed at the BBB but is also detected in other brain parenchy-
mal regions [24,25]. CYP1A1 has also been identified in human
brain and localized to the cortical regions, midbrain, basal ganglia,
and cerebellum [26]. According to reports, CYP1A2 has been found
in most brain regions examined across both humans and rats
[9,27,28]. CYP1B1 was also shown to be expressed in various brain
regions and at the BBB interface [7,24,25].
The existence of these enzymes in BBB endothelial cells, togeth-
er with the observation that serotonin and noradrenergic trans-
porters are also present on the surface of ECs in the brain [29],alludes to the possible role of serotonin and norepinephrine in
regulating vascular flow along with a xenobiotic role. A role for
astrocytes in the control of cerebral microcirculation mediated by
P450 2C11-catalyzed conversion of arachidonic acid (AA) to epox-
yeicosatrienoic acids (EETs) has also been identified [30]. The P450
metabolites of AA are of particular interest because of their vaso-
active properties and their involvement in vascular control and
cerebrovascular disease, such as subarachnoid hemorrhage (SAH)
and ischemic stroke [30,31]. The relative role of these CYP enzymes
in relation to changes that can occur as part of the neurodegener-
ative process and subsequent effects on the BBB could be further
explored. Additionally, these CYP enzymes might have an impor-
tant role in regulating the levels of endogenous GABA, which is
thought to participate in brain cholesterol homeostasis as well as
in the elimination of retinoids [32].
Routes of drug biotransformation
Pharmacokinetic processes involve drug absorption, distribution,
metabolism (biotransformation), and excretion. The pharmacody-
namic processes involve target site of action, and pharmacological
and toxicological effects. Overall, these processes determine serum
drug levels, the onset, peak, and duration of drug actions, half-life,
and therapeutic and adverse drug effects (Fig. 3). Biotransformation
is mediated by drug-metabolizing enzymes, leading to the conver-
sion of (i) the active drug into inactive metabolite; (ii) the active
drug into active by-products; (iii) the inactive drug into active drug
(prodrug); or (iv) the drug into a harmful metabolite. Drug bio-
transformation occurring in the brain is proposed to locally impact
pharmacological responses and contribute to adverse effects. Al-
though CYP levels in the brain are generally lower than in the liver,
changes in CYP brain biotransformation were proposed to contrib-
ute to CNS drug failure or toxicity [33].www.drugdiscoverytoday.com 1611
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TABLE 1
Expression of CYP450 drug-metabolizing enzymes and their specific localization in the brain
Gene product Species Brain region Expression Refs
Endothelial cells
CYP1B1 Mouse, human BBB Protein [5,25,101,107]
CYP2J2 Human Cortex, microvessels mRNA [5,101]
CYP2E1 Mouse, human BBB Protein [15]
CYP3A4 Human, rat Cortex, frontal lobe, thalamus mRNA, protein [7,8,26,108–110]
CYP3A11 Mouse Hypothalamus, hippocampus, olfactory bulb, cerebellum Protein [111]
CYP3A13 Mouse Hippocampus, hypothalamus, olfactory bulb Protein [111]
Astrocytes
CYP1A1 Mouse, rat, human Multiple brain regions Protein, mRNA [112]
CYP1A2 Rat, human Cortex, cerebellum, brain stem, thalamus, hippocampus, striatum Protein, mRNA [9,27,28]
CYP2B6 Human Cortex, cerebellum, hippocampus Protein [18,113]
CYP2C9 Human mRNA [108]
CYP2C11 Rat Multiple brain regions [114]
CYP2C29 Mouse Astrocytes Protein [115]
CYP2E1 Mouse, human BBB Protein [15]
CYP3A11 Mouse Hypothalamus, hippocampus, olfactory bulb, cerebellum Protein [111]
CYP3A13 Mouse Hippocampus, hypothalamus, olfactory bulb Protein [111]
Neurons
CYP1A1 Mouse, rat, human Multiple brain regions Protein, mRNA [112]
CYP1A2 Rat, human Cortex, cerebellum, brain stem, thalamus, hippocampus, striatum Protein, mRNA [9,27]
CYP2B1 Rat Frontal cortex, striatum, olfactory tubercle Protein, mRNA [16]
CYP2B6 Human Cortex, cerebellum, hippocampus Protein [113]
CYP2B10 Mouse Hippocampus Protein [116]
CYP2C19 Mouse Hippocampus of fetal brain mRNA [117]
CYP2D1 Rat Multiple brain regions Protein, mRNA [11]
CYP2D4 Rat Substantia nigra, olfactory bulb, cerebellum [32]
CYP2D6 Human Multiple regions, especially hippocampus, cortex, cerebellum mRNA, protein [26,40]
CYP2E1 Mouse, rat, human Cortex, cerebellum, basal ganglia, hippocampus, medulla oblongata, pons mRNA, protein [5,15,84,85]
CYP2G Rat Olfactory bulb [118]
CYP2J9 Mouse Cerebellum, hippocampus, cerebral cortex, brain stem mRNA [119]
CYP3A4 Human, rat Cortex, frontal lobe, thalamus mRNA, protein [7,8,26,108–110]
CYP3A9 Rat Cerebellum mRNA [120]
CYP3A11 Mouse Hypothalamus, hippocampus, olfactory bulb, cerebellum Protein [111]
CYP3A13 Mouse Hippocampus, hypothalamus, olfactory bulb Protein [111]
CYP4A Rat Cortex, cerebellum, brain stem, hypothalamus mRNA [121]
Active drug to inactive
metabolites
Active drug to active by-products Inactive drug to active/
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FIGURE 3
Potential routes to drug biotransformation. Specific pharmacokinetic processes trigger subsequent pharmacodynamics processes that determine many important
aspects of drug therapy. Biotransformation events are not limited to the liver and gut, because they are also mediated by drug-metabolizing enzymes expressed in
regions of the brain.
1612 www.drugdiscoverytoday.com
R
eview
s
K
E
Y
N
O
T
E
R
E
V
IE
W
Drug Discovery Today  Volume 21, Number 10 October 2016 REVIEWS
R
ev
ie
w
s
 K
E
Y
N
O
T
E
R
E
V
IE
WEvidence suggests that CYP isoforms in the brain are also
involved in the metabolism of many endogenous substances,
such as neurosteroids, monoaminergic neurotransmitters, vita-
mins, and AA [9,11,18,34]. CYP2D mediates the hydroxylation of
tyramine to dopamine in the brain, which has been demonstrated
in two experimental rat models by using reserpinized rats and
blocking the classical pathway of dopamine synthesis from tyro-
sine [35]. It has been further documented that CYP2D in rat brain
has the ability to metabolize drugs and can be inhibited or
induced in vivo, independently of hepatic CYP2D involvement
[36]. Given that CYP2D metabolically activates codeine to mor-
phine, which is required for codeine analgesia, the authors
showed that nicotine treatment increased codeine analgesia
through the induction of brain CYP2D in rats during activation
of codeine to morphine [37]. Similarly, this has been demonstrat-
ed to be the case with CYP2B. Manipulating rat CYP2B metabolic
activity in the brain (and not liver) altered the sleep timing
(circadian rhythm) induced by the anesthetic propofol, which
is metabolically inactivated by CYP2B [38]. The neurotoxicity
from chlorpyrifos (an insecticide), which is metabolically activat-
ed by CYP2B, has also been reported [39]. Therefore, these exam-
ples suggest a role of CYPs across brain regions, potentially
affecting the drug response independently from hepatic mecha-
nisms [34,36,38,39].
The relevance of brain P450 expression might become even
greater in the setting of disease states, including psychiatric dis-
eases (e.g., depression or schizophrenia), vascular alteration (e.g.,
ischemic stroke), neurodegenerative diseases (e.g., Alzheimer’s
and Parkinson’s diseases; AD and PD), and epilepsy. Here, we
provide an overview of the available data.
Psychiatric diseases
Constitutive expression of CYP2D in human brain neurons
indicates its possible role in the metabolism of psychoactive
drugs [40]. CYP2D mRNA was found to be expressed in neurons
of the cerebral cortex, Purkinje and granule cell layers of the
cerebellum, reticular neurons of the midbrain, and pyramidal
neurons of the hippocampus. Additional studies demonstrated
the presence of the CYP2D protein in the cortex, cerebellum,
midbrain, striatum, and thalamus of human brain and its asso-
ciation with psychoactive drug metabolism [40]. Neuroimaging
studies have recently shown an effect of CYP2D6 polymorphism
on brain functions, vulnerability to mental disorder [41], and
extrapyramidal adverse effects of neuroleptic and antidepres-
sants [42]. Other CYPs, such as the CYP3A4, are becoming
increasingly important in psychopharmacology as a result of
their involvement in the metabolism of a range of antidepres-
sants and benzodiazepines [41,43].
Pharmacogenomics studies conducted on patients with schizo-
phrenia showed antipsychotic drug metabolism via CYP1A2,
where a putative gene–gene interaction between dopamine D-3
receptors and CYP1A2 was documented [44]. Neuropsychiatric
differences have been reported among individuals with genetic
variations in CYP2D6, which metabolizes the endocannabinoid
anandamide and influences brain function [45]. Another study
suggested that the abundant presence of CYPs in selective cell
populations has a role in maintaining brain function in psychiatric
disorders [9].Ischemic stroke
Ischemic strokes occur as a result of an obstruction within a blood
vessel supplying blood to the brain. Such sudden loss of blood
circulation to an area of the brain results in a corresponding loss of
neurologic function [46]. Cerebral blood flow (CBF) is a crucial
component of nutrient supply to the brain; this is achieved by
adapting regional CBF to local neural activity (autoregulation)
[46]. The basis of CBF functionality lies in the hyperemic response,
which occurs because of an increase in blood flow to tissues
mediated by vasoactive ions and metabolites, which are them-
selves released from astrocytes and neurons in response to neural
activity [46]. Another possible mechanism contributing to auto-
regulation involves the upregulation of astrocytic CYP2C11 epox-
ygenases, which mediate the conversion of AA into the active
vasodilator epoxyeicosatrienoic acid; the latter appeared to reduce
experimental stroke damage in a rodent model [47]. Evidence
suggests that v-hydroxylases (e.g., CYP4A) use AA to generate
the vasoconstrictor 20-hydroxyeicosatetraenoic acid (HETE),
which is implicated in the regulation of myogenic tone and
inflammation [48]. CYP1B1 might also regulate CBF [25,49], be-
cause it metabolizes prostanoids and eicosanoids [9]. In summary,
P450 epoxygenase and AA metabolism, acting via the P450-de-
pendent pathway, could contribute to CBF regulation [47,50].
Neurodegenerative diseases
PD is a progressive neurodegenerative disease characterized by loss
of dopamine neurons in the substantia nigra [51]. Exposure to
environmental toxins, including pesticides, is a risk factor for PD
[51]. A case report suggested that decreased levels of the CYP2D6
gene translates into a higher risk of developing PD [52], while
another report indicated that risk is further increased with pesti-
cide exposure [51]. In rat models, it has been proven that brain
CYP2D catalyzes the conversion of tyramine into dopamine [35].
Therefore, the loss of dopamine because of decreased CYP2D6-
activated gene expression in the brain could be a potential factor in
the onset of PD [35]. Another study investigated the link between
single nucleotide polymorphisms (SNPs) in CYP17 and CYP19
genes and cumulative incidence of AD in subjects with Down
syndrome [53]. The authors suggested genetic variations in specific
CYPs to be associated with increased susceptibility to AD affecting
cognition in these subjects [53]. Furthermore, carrying high-risk
alleles or mutation in both CYP17 and CYP19 genes was associated
with a fourfold increased risk for AD, as well as the binding of
elevated sex hormones (as endogenous CYP substrates) to globulin
in postmenopausal women. This suggests that genes contributing
to estrogen bioavailability influence the risk of AD in women with
Down syndrome. Another study reported that the APP23 mouse
model of AD presented an abundance of amyloid-b peptides
following inhibition of CYP46A1 expression, which resulted in
brain cholesterol accumulation and neuronal death, suggesting a
neuroprotective role of brain CYP [54].
Cancer
CYP3A4/5 metabolizes antineoplastic molecules (e.g., ifosfamide,
vinblastine, etoposide, and doxorubicin) and contributes to drug
resistance in patients with cancer [55]. The presence of P450s in
tumor cells might be part of a pleiotropic response to tumor
development, because certain P450 enzymes provide an essentialwww.drugdiscoverytoday.com 1613
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FIGURE 4
Cytochrome P 3A4 (CYP3A4) localization in human temporal lobe epileptic
(TLE) brain. Representative images showing CYP3A4 localized in the
cerebrovasculature (a) and neurons (b) of a human drug-resistant epileptic
brain evaluated by immunohistochemistry. The autoptic brain tissues
obtained from cardiomyopathic subjects (non-neurological case) showed
lower levels of CYP3A4 compared with drug-resistant epileptic brains (c,d).
Colocalization was evaluated with a neuronal marker staining the neuronal
nuclei [NEUN (b)] and glial marker [Glial fibrillary acidic protein, GFAP (a,c)].
DAPI [(40 ,6-diamidino-2-phenylindole (d)] was used as nuclear counterstain.
Data from [7,8].
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methoxyestradiol, or by activating tumor-promoting compounds,
such as 4-hydroxyestradiol [56]. This underscores the role of CYPs
in controlling the balance between cytotoxicity and protection. It
was shown that the levels of ellipticine required to kill a glioblas-
toma cell line are dependent on CYP1A1-, CYP1B1-, and CYP3A4-
mediated biotransformation, implying an association of P450s
with anticancer activity [57].
The cancer-preventative agent resveratrol (a natural constituent
of red wine) undergoes metabolism via the CYP450 enzyme
CYP1B1 to form a metabolite (piceatannol) with antileukemic
properties, suggesting that CYP1B1 in tumors functions as a
growth-suppressor enzyme [58]. Tumor cells are exposed to hyp-
oxic conditions, with cells alternating between hypoxic and aero-
bic conditions [59]. In such cases, CYPs are capable of supporting
the oxidative, peroxidative, and reductive metabolism of a range
of xenobiotic and endogenous compounds, including the genera-
tion of active AA metabolites [56]. Therefore, in a hypoxic envi-
ronment, P450 enzymes might function as reductive enzymes
[56,60].
Epilepsy and multiple drug resistance
Patients with epilepsy whose seizures do not respond to antiepi-
leptic drug (AED) therapy are considered drug resistant (DRE)
[61,62]. Several factors regulate the efficacy of AEDs, including
metabolism, transport of drugs to the epileptic focus, and target
sensitivity. The mechanisms underlying the development of DRE
are complex and not fully understood. Drug resistance depends on
several clinical aspects, including etiology, seizure onset at an early
age, type of epileptic syndrome and seizure, and structural brain
abnormalities or lesions [4,61,62]. Reports suggest that DRE is a
progressive disorder, which, if controlled early, could be prevented
from developing into a full syndrome (refractory epilepsy or DRE)
[61,63]. There have also been several hypotheses proposed for
multiple drug resistance [61,64]. The difficulty lies in its identifi-
cation at an early stage in patients who are likely to progress to
intractability. Furthermore, reports indicate that drug resistance
might arise during the course of epilepsy regimen, even after an
initially positive response to AEDs was seen, suggesting that epi-
lepsy-related acquired changes affecting AED efficacy or progres-
sion of the disease are involved in intractability [61,63].
Recent findings suggest that the BBB significantly contributes to
the phenomenon of multiple drug resistance [3,7,20,62,65]. BBB
changes have been observed in brain tissue of patients with
epilepsy and in experimental models [3,4,7,62,66,67]. It has been
illustrated that multiple drug transporter proteins contribute to
the phenomenon of drug resistance in epilepsy [3,4,8,62,66,67].
The role of neurovascular P450s in the epileptic brain was also
recently proposed [7,8]. AEDs could be locally metabolized, result-
ing in the loss of therapeutic efficacy or production of neurotoxic
molecules [20]. AEDs, such as oxcarbazepine, carbamazepine, and
phenytoin, are associated with CYP3A4 in human hippocampal
pyramidal neurons [68]. As a result, induction of CYP3A4 metab-
olism in the brain can alter brain function. An example of CYP3A4
localization in the microvessels and neurons of human drug-
resistant epileptic brain is shown in Fig. 4a,b by immunohis-
tochemistry. Remarkably, autopsy brain tissues (Fig. 4c,d) from
two cardiomyopathic subjects (non-neurological case) displayed1614 www.drugdiscoverytoday.comlower levels of CYP3A4 relative to DRE brains. In addition, earlier
studies showed CYP3A4 expression (in protein and mRNA) to be
significantly elevated in epileptic brain endothelial cells, isolated
from brain resections of DRE, when compared with commercially
procured, control brain endothelial cells [7,8]. Patients treated
with AED have higher expression of both androgen receptors
and CYP3A4 in the hippocampus compared with patients with
untreated epilepsy [68]. Similarly, administration of phenytoin to
mice leads to the induction of androgen receptor expression in the
hippocampus [69]. Expression and function of CYP2E1 in human
drug-resistant epileptic brain and rodent models of seizure were
also observed [15].
Drug interactions and P450 enzymes
The effect of P450 metabolism becomes even more significant in
polytherapies. This is relevant when a drug modulating P450
expression and activity is co-administered with a compound that
undergoes P450 biotransformation. The results are a deviation
from the expected pharmacokinetic or pharmacodynamic drug
profiles [70]. For instance, a recent study performed on primary
brain cells (endothelial and neuronal) showed neurotoxic inter-
actions between carbamazepine and sertraline occurring at sub-
therapeutic concentrations, and possibly linked to an increased
CYP3A4-mediated production of reactive carbamazepine metab-
olites [33]. Other reports suggested that children with refractory
epilepsy treated with clobazam (CLB) and cannabidiol (CBD)
experience drug–drug interactions owing to the fact that CLB
and CBD metabolism involves a P450 pathway [71]. The reduction
in CLB dosage alleviated the adverse effects because subjects were
found to have tolerated CBD.
Drug Discovery Today  Volume 21, Number 10 October 2016 REVIEWS
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hydropyridine (MPTP) neurotoxicity in mice has also been inves-
tigated. A neurotoxic metabolite 1-methyl-4-phenylpyridinium
ion (MPP+) derived from MPTP was increased in brain slices from
phenobarbital-treated mice (a known P450 inducer) and de-
creased in brain slices pretreated with a CYP inhibitor [72]. Pre-
dicting the pharmacokinetic properties of a drug might become
more complex when co-administering drugs that inhibit P-glyco-
protein, including clarithromycin, erythromycin, ritonavir, or
verapamil, as well as P-glycoprotein inducers, such as rifampicin
and St. John’s Wort. In addition, P-glycoprotein substrates over-
lap with those of CYP3A4 and most P-glycoprotein inhibitors are
also inhibitors of CYP3A4. As a result, drug interactions could
result from the influence on transporter and metabolic mecha-
nisms in the liver or brain [70,73]. This indicates that CNS drugs
should be selected with more caution while considering the brain
CYPs. Examples are provided in Table 2. The antiepileptic drug
phenytoin induces CYP2B and CYP3A enzymes in the mouse
brain, which results in altered brain testosterone metabolism
[74]. Some drugs can also induce or repress their own local
metabolism in the brain, which is P450 mediated. For example,
clozapine is inactivated by CYP2D enzymes. Given that drugs are
co-administered with clozapine, induction of brain CYP2D by
clozapine could result in faster CYP2D-mediated metabolic inac-
tivation of other substrates, including antidepressants, or in-
creased activation of the oral opiate codeine to morphine.
In addition, some of these centrally acting drugs could modifyTABLE 2
CYP isoenzymes and CNS-acting drugs as substrates (exogenous or 
CYP enzymes Exogenous substrates (drugs, xenobiotics, and
other compounds)
Endogen
CYP1A1 7-Ethoxyresorufin, nicotine, 7,12-dimethylbenz(a)
anthracene (DMBA), rifampicin
Melatoni
CYP1A2 Caffeine, phenacetin, diazepam, haloperidol,
aspartame, phenytoin, primidone, 7-ethoxyresorufin
AA, estra
CYP1B1 Arachdonic acid, stilbene, b-naphthoflavone, 7,12-
dimethylbenz(a) anthracene (DMBA), nicotine
Melatoni
CYP2B6 Methadone, meperidine, ethanol, nicotine,
pentobarbital, phencyclidine, propofol, sertraline,
phenytoin, chlorpyrifos, cyclophosphamide, N,N-
diethyl-m-toluamide (DEET), efavirenz, ifosfamide,
malathion, paraquat, parathion
17b-Estra
testoster
CYP2C Felbamate, fluoxetine, phenobarbital, (S)- warfarin,
phenytoin, valproic acid, topiramate, carvedilol,
celecoxib, carbamazepine, primidone, rifampicin
Testoster
harmine,
CYP2D Amitriptyline, brofaromine, clomipramine, codeine,
opiate, citalopram, clozapine, desipramine,
dextromethorphan, morphine, fluoxetine,
fluvoxamine, haloperidol, imipramine, mianserin,
mirtazapine, nicotine, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), parathion
5-Methox
tyramine
CYP2E1 Isoflurane, phenytoin, phenobarbital, acetaminophen,
acetone, aniline, benzene, carbon tetrachloride,
chloroform, chlorzoxazone, ethanol, nicotine,
aspartame
17b-Estra
prostagla
CYP3A Carbamazepine, oxcarbamazepine, phenytoin,
caffeine, ketoconazole, nifedipine, dexamethasone,
felbamate, pesticides
Steroids,CYP-mediated brain metabolism of endogenous neurochemicals,
including tyramine to dopamine by CYP2D6 [35] and the metab-
olism of neurosteroids by CYP3A [75], which in turn can modify
therapeutic outcome.
Additional factors influencing P450 function in the
brain
Hemodynamic and rheological factors as regulators of CYP
expression and function
Laminar shear stress has been proven to have a key role in
modulating CYP expression in vitro [7,20]; this supports the
hypothesis that turbulent flow (e.g., aneurysm) or transient loss
of flow (e.g., stroke or ischemia) can influence CYP expression.
Microarray studies demonstrated that the gene expression of
CYP1A1, CYP1B1, and CYP3A4 is upregulated by shear stress in
cultured human brain endothelial cells [7]. Han et al. showed that
the aryl hydrocarbon receptor regulates CYP1A1 expression and
cell cycle in vascular endothelial cells under laminar shear stress
conditions [76]. Furthermore, the duration of shear stress influ-
ences CYP1A1 and CYP1B1 expressions in human endothelial
cells [49]. Reports suggest that, in rat brain slices and the isolated
retina, the fluctuation of intracellular calcium concentrations in
astrocytes affects vessel constriction. This event is mediated by
CYP4A and occurs during the conversion of AA to 20-hydroxy-
eicosatetraenoic acid [77]. These reports suggest that cerebral
blood flow directly or indirectly affects brain CYP expression
and activity.endogenous)
ous substrates Refs
n, estradiol, AA, progesterone [23–25]
diol and other steroids, fatty acids [9,18,23,24]
n, estradiol [9,16,18]
diol, anandamide, AA, estrone, serotonin,
one
[19,38,39,74,83,122]
one, progesterone, AA, serotonin, harmaline,
 linoleic acid, melatonin
[29,30,117,123]
ytryptamine, anandamide, progesterone, [9,11,18,32,34–37,45,98,122]
diol, arachidonic acid, linoleic acid, oleic acid,
ndin
[15,19,84,85,90]
 progesterone, testosterone, estradiol [20,33,43,69,73–75,77,110,120]
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Hepatic P450 mutations profoundly alter systemic drug metabo-
lism and distribution. However, the possibility that mutated or
polymorphic variants of P450 exist in the brain is understudied.
The latter is clinically relevant because it potentially alters brain
drug metabolism. Indirect evidence derives from the association
between CYP17 and CYP19 variants and onset of AD [53]. Another
example is the genetic variation of CYP2D6 that was linked to
neuropsychiatric phenotype differences among patients. The lat-
ter could be related to dissimilar interactions of CYP2D6 with
endogenous substrates (e.g., anandamide) [45].
Evidence also exists supporting a role for the CYP2D6 geno-
type in brain function during cognitive tests performed on
individuals and measured using fMRI [78]. A range of CYP2D6
activity is observed among different individuals because the
gene encoding CYP2D6 is highly polymorphic. Approximately
7% of Caucasians have gene variants leading to a lack of the
functional enzyme and, therefore, are referred to as CYP2D-poor
metabolizers [79]. Both hepatic and brain levels of CYP2D6 are
reduced in genetic CYP2D6-poor metabolizers [11]. CYP2D6-
poor metabolizers might have observable differences in brain
function and behavior that could result from the altered pro-
duction of endogenous signaling molecules [34]. Increased anx-
iety and impulsivity have been associated with a CYP2D6-poor
metabolizer [80]. By contrast, CYP2D6-extensive metabolizers
have increased cerebral activity in the thalamus and hippocam-
pus, two regions that have high expression of CYP2D6 protein
and mRNA [81]. Along the same lines of evidence, polymorphic
CYP2C19, which metabolizes sex hormones and 5-hydroxytryp-
tamine, was associated with specific personality traits (such as
temperament and character assessment) within 487 Japanese
healthy volunteers (male and female) [82]. Another report sug-
gested that genetic polymorphism affecting the activity of pri-
marily CYP2B6 and CYP3A4 is associated with the neurotoxicity
of efavirenz during antiretroviral drug therapy in patients with
HIV [83].
Substance abuse
A link between alcohol consumption, smoking, and increased
levels of CYP2B6, CYP2E1, and CYP2D6 in specific brain regions
has been observed [16,19,84,85]. This is a significant adaptive
response to chronic exposure to ethanol or nicotine. Addicted
subjects can respond differently to drugs and endogenous com-
pounds because of the elevated levels of selected CYPs in the brain
[16,19,84,85].
Another example is fluoxetine, a selective serotonin reuptake
inhibitor (SSRI), that was found to inhibit CYP enzymes and that
interferes with the metabolism of cocaine in rats [86]. Another
study performed in rodents showed the interaction of cocaine and
nifedipine (a 1,4-dihydropiridine calcium channel blocker) affect-
ing total P450 levels exclusively in the liver; however, no signifi-
cant alteration in P450 levels was identified in the brain. This study
suggested that the combination of drugs and dosages impacts the
total P450 levels in the brain [87]. Evidence also suggests that
transient exposure to fluoxetine in early postnatal days leads to
decreased brain AA metabolism and CYP4A levels in adult mice,
possibility related to long-term behavioral alterations in brain
development [88,89].1616 www.drugdiscoverytoday.comDietary factors
Aspartame consumption and insulin treatment in a juvenile dia-
betic rat model were shown to upregulate CYP2E1 and CYP3A2
isozyme levels in the brain [90]. Activity of CYP2E1 can induce the
production of oxygen radicals, and both CYP2E1 and CYP3A2
metabolize endogenous or exogenous substances, increasing brain
susceptibility to neurotoxins [90].
Hyperlipidemia affects cerebral blood flow by the formation of
plaque leading to atherosclerosis and coronary heart disease [91].
Hyperlipidemia was also linked to brain CYP modifications. It has
been shown that induction of CYP2E1 in the brain occurs in
hyperlipidemia subjects, or after associated ischemia-reperfusion
(IR) injury [92]. Furthermore, CYP2E1 induction can contribute to
the production of tissue-damaging radicals, inflammatory re-
sponse, and neuronal apoptosis. Therefore, the occurrence of
hyperlipidemia in patients with cerebral ischemia presents a
higher threat to neuronal degeneration, because of CYP2E1 ex-
pression [92].
Environmental factors
CYP enzyme levels in brain can impact the distribution of envi-
ronmental molecules, modifying their pharmacological and/or
toxicological effects [93]. CYPs and other enzymes, such as car-
boxylesterases and paraoxonase 1, have the capacity to metabolize
pesticides, which could interfere with the metabolic changes
documented in pregnant mice exposed to such environmental
contaminants, further impacting the developing brain in the
offspring [93,94]. In another study, exposure to uranium in rats
was linked to molecular changes in the regulation of cerebral
cholesterol metabolism, with an involvement of the cholesterol-
catabolizing enzyme, CYP46A1 [95]. Along with CYPs, the role of
P-glycoprotein is also associated with environmental toxins, such
as heavy metals and pesticides [96]. Chlorpyrifos, a commonly
used insecticide that can be activated by CYP2B into the acetyl-
cholinesterase inhibitor chlorpyrifos-oxon, caused cholinergic
overstimulation and neurotoxicity in rats [39]. Furthermore,
one study reported that, in rats, acute exposure to chlorpyrifos
resulted in neurochemical-behavioral symptoms indicating possi-
ble neurotoxicity [97]. As described above, subjects who are
CYP2D6-poor metabolizers are at higher risk of developing PD
[52], and this risk is further increased when individuals are exposed
to pesticides [98]. Therefore, CYP2D6 metabolism could have a
neuroprotective effect against PD risk factors, including pesticide
exposure.
CYP regulation in the brain
The expression of P450 enzymes in the liver and intestine is
regulated by the pregnane X receptor (PXR), constitutive andros-
tane receptor (CAR), aryl hydrocarbon receptor (AHR), and gluco-
corticoid receptor (GR). These nuclear receptors (NRs) respond to
xenobiotics or endogenous compounds entering the cell by mod-
ulating downstream enzyme targets [99]. In the CNS, NRs also
control the regulation of CYPs as well as drug transporters [5,100].
However, the NR mechanism of CYP regulation in the brain could
be different from that in the liver and needs to be better under-
stood. In the human brain, several NRs have been detected,
including AHR, PXR, farnesoid X receptor (FXR), CAR, retinoid-
x-receptors (RXRa and b), and peroxisome proliferator-activated
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AhR agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in-
creased mRNA expression of CYP1A1 and CYP1B1 in the human
brain cell line hCMEC/D3 [5,101]. In a recent study, Jacob et al.
showed the differential modulation of CYP1B1 and ABCB1/
ABCG2 expression in hCMEC/D3 cells following exposure to
environmental pollutants, such as TCDD, suggesting AhR involve-
ment in the TCDD-mediated increase in CYP1B1 expression [100].
Other evidence also indicates the expression of PXR and CAR in
the mammalian cerebrovasculature [2,102].
Reports of varied NR distribution among brain regions are
documented. CAR, for example, was detected only in the human
caudate nucleus [103]; PXR was expressed at highest levels in the
human thalamus, pons, and medulla [104]; PPAR and RXR were
expressed highly in the rat brainstem, but at low levels in the
substantia nigra [105]; AhR was expressed highly in the rat olfac-
tory cortex but at low levels in the amygdala [106]. Much remains
to be understood in terms of the expression of NR across the brain
regions, their cellular specificity, and their role in regulating brain
CYPs. Furthermore, whether the PXR/CAR system regulates CYP
expression in neurological diseases and its contribution to CNS
drug resistance remains to be elucidated.
Relevance of brain P450 to drug discovery
Drug discovery and the development of next-generation medica-
tion revolve around several critical elements and factors that
regulate brain pharmacokinetic and drug metabolism. Under-
standing how and where brain CYPs function could be exploited
for drug development (e.g., prodrugs transformed into activecompounds) might in turn facilitate the development of novel
therapeutics. Knowledge of CYP and transporter function in the
neurovascular interface could increase our ability to deliver active
forms of drugs specifically to the brain and minimize drug inter-
actions. Although there have been substantial advances in our
understanding of brain CYPs and distribution, much remains to be
explored, particularly the interindividual variability in response to
CNS drugs, and risk factors controlling neurotoxicity and brain
disorders.
Concluding remarks
In conclusion, the role of cytochrome P450 enzymes in the
brain is becoming increasingly evident. In addition, a role in
promoting or hampering neuronal survival has been demon-
strated, suggesting that these enzymes have been unjustly
neglected in favor of other mechanisms, such as drug extrusion
transporters. Further understanding of this complex molecular
network that interfaces the xenobiotic world with neuronal
activity could help to reduce undesirable adverse effects of
current and future drugs.
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